{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:13Z","timestamp":1790686213630,"version":"4.1.0"},"reference-count":228,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41375-019-0388-x","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T17:15:17Z","timestamp":1548868517000},"page":"844-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)"],"prefix":"10.1038","volume":"33","author":[{"name":"on behalf of the European Conference on Infections in Leukemia (ECIL)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-2466","authenticated-orcid":false,"given":"Georg","family":"Maschmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-1237","authenticated-orcid":false,"given":"Julien","family":"De Greef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Nosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thiebaut-Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Franquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A.","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"388_CR1","unstructured":"Blincyto summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/blincyto-epar-product-information_en.pdf . Accessed 24 December 2018."},{"issue":"5","key":"388_CR2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","volume":"57","author":"Maria-Elisabeth Goebeler","year":"2016","unstructured":"Goebeler ME, Bargou R. Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016;57:1021\u201332.","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"388_CR3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"Kemeng Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.","journal-title":"Experimental Hematology & Oncology"},{"issue":"5891","key":"388_CR4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R. Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974\u20137.","journal-title":"Science"},{"key":"388_CR5","doi-asserted-by":"crossref","unstructured":"N\u00e4gele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, et al. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL. Exp Hematol Oncol. 2017;6:14.","DOI":"10.1186\/s40164-017-0074-5"},{"issue":"9","key":"388_CR6","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1038\/bcj.2014.64","volume":"4","author":"G Zugmaier","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244.","journal-title":"Blood Cancer Journal"},{"issue":"3","key":"388_CR7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","volume":"128","author":"V. G. Bhoj","year":"2016","unstructured":"Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128:360\u201370.","journal-title":"Blood"},{"issue":"9","key":"388_CR8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"Hagop Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"388_CR9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"Max S Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"The Lancet Oncology"},{"issue":"2","key":"388_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00277-017-3153-0","volume":"97","author":"Thomas S. Y. Chan","year":"2017","unstructured":"Chan TSY, Kwong YL. Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy. Ann Hematol. 2018;97:371\u20133.","journal-title":"Annals of Hematology"},{"issue":"10","key":"388_CR11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2017.1338270","volume":"16","author":"Anne C. Wilke","year":"2017","unstructured":"Wilke AC, G\u00f6kbuget N. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf. 2017;16:1191\u2013202.","journal-title":"Expert Opinion on Drug Safety"},{"issue":"6","key":"388_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1078155217713363","volume":"24","author":"Ryan K DasGupta","year":"2017","unstructured":"DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. 2018;24:453\u201367.","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"3","key":"388_CR13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"N. M. Okeley","year":"2010","unstructured":"Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888\u201397.","journal-title":"Clinical Cancer Research"},{"key":"388_CR14","unstructured":"Adcetris summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002455\/WC500135055.pdf . Accessed 22 November 2017."},{"issue":"2","key":"388_CR15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","volume":"90","author":"Roberto Chiarle","year":"1999","unstructured":"Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157\u201364.","journal-title":"Clinical Immunology"},{"issue":"8","key":"388_CR16","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/eji.200939424","volume":"39","author":"Vasileios Bekiaris","year":"2009","unstructured":"Bekiaris V, Gaspal F, Kim MY, Withers DR, Sweet C, Anderson G, et al. Synergystic OX40 and CD30 signals sustain CD8+T cells during antigenic challenge. Eur J Immunol. 2009;39:2120\u20135.","journal-title":"European Journal of Immunology"},{"issue":"1-3","key":"388_CR17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12026-013-8464-1","volume":"57","author":"Hiromi Muta","year":"2013","unstructured":"Muta H, Podack ER. CD30: from basic research to cancer therapy. Immunol Res. 2013;57:151\u20138.","journal-title":"Immunologic Research"},{"key":"388_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tube.2016.10.006","volume":"102","author":"Nancy D. Mar\u00edn","year":"2017","unstructured":"Mar\u00edn ND, Garc\u00eda LF. The role of CD30 and CD153 (CD30L) in the anti-mycobacterial immune response. Tuberculosis. 2017;102:8\u201315.","journal-title":"Tuberculosis"},{"issue":"18","key":"388_CR19","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"Anas Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"388_CR20","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"Barbara Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"Journal of Clinical Oncology"},{"issue":"9980","key":"388_CR21","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"Craig H Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"The Lancet"},{"key":"388_CR22","doi-asserted-by":"crossref","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","DOI":"10.1056\/NEJMoa1708984"},{"key":"388_CR23","doi-asserted-by":"crossref","unstructured":"Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555\u201366.","DOI":"10.1016\/S0140-6736(17)31266-7"},{"issue":"2","key":"388_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","volume":"19","author":"Owen A O'Connor","year":"2018","unstructured":"O\u2019Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international multicenter, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19:257\u201366.","journal-title":"The Lancet Oncology"},{"key":"388_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2359437","volume":"2016","author":"Yasmin Sabet","year":"2016","unstructured":"Sabet Y, Ramirez S, Rosell Cespedes E, Rensoli Velasquez M, Porres-Mu\u00f1oz M, Gaur S, et al. Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory Hodgkin\u2019s lymphoma. Case Rep Pulmonol. 2016;2016:2359437.","journal-title":"Case Reports in Pulmonology"},{"issue":"7","key":"388_CR26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/cas.12435","volume":"105","author":"Michinori Ogura","year":"2014","unstructured":"Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, et al. Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105:840\u20136.","journal-title":"Cancer Science"},{"issue":"6","key":"388_CR27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1179\/1973947813Y.0000000095","volume":"25","author":"Matteo Bassetti","year":"2013","unstructured":"Bassetti M, Pecori D, Righi E, Brillo F, Cadeo B, Venturini S, et al. HSV-1 cutaneous infection in a patient with Hodgkin\u2019s lymphoma treated with brentuximab vedotin. J Chemother. 2013;25:381\u20132.","journal-title":"Journal of Chemotherapy"},{"issue":"3","key":"388_CR28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","volume":"120","author":"A. K. Gopal","year":"2012","unstructured":"Gopal AK, Ramchandren R, O\u2019Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120:560\u20138.","journal-title":"Blood"},{"key":"388_CR29","doi-asserted-by":"crossref","unstructured":"Tudesq JJ, Vincent L, Lebrun J, Hicheri Y, Gabellier L, Busetto T, et al. Cytomegalovirus infection with retinitis after brentuximab vedotin treatment for CD30+lymphoma. Open Forum Infect Dis. 2017;4:ofx091.","DOI":"10.1093\/ofid\/ofx091"},{"key":"388_CR30","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: new boxed warning and contraindication for Adcetris (brentuximab vedotin), issued on 1\/13\/2012. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm287668.html . Accessed 6 August 2018."},{"issue":"16","key":"388_CR31","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","volume":"120","author":"Kenneth R. Carson","year":"2014","unstructured":"Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120:2464\u201371.","journal-title":"Cancer"},{"issue":"8","key":"388_CR32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","volume":"15","author":"Dennis W. Raisch","year":"2016","unstructured":"Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system. Expert Opin Drug Saf. 2016;15:1003\u201311.","journal-title":"Expert Opinion on Drug Safety"},{"issue":"4","key":"388_CR33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajh.20492","volume":"80","author":"Julio Garc\u00eda-Su\u00e1rez","year":"2005","unstructured":"Garcia-Suarez J, de Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80:271\u201381.","journal-title":"American Journal of Hematology"},{"issue":"15","key":"388_CR34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1212\/WNL.0b013e3181f73600","volume":"75","author":"K. L. Amend","year":"2010","unstructured":"Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75:1326\u201332.","journal-title":"Neurology"},{"issue":"9","key":"388_CR35","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"Johan Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397\u2013404.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"388_CR36","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","volume":"94","author":"Michael Sandherr","year":"2015","unstructured":"Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies\u2014update of the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94:1441\u201350.","journal-title":"Annals of Hematology"},{"issue":"Suppl_2","key":"388_CR37","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3949\/ccjm.78.s2.09","volume":"78","author":"L. CALABRESE","year":"2011","unstructured":"Calabrese L. A rational approach to PML for the clinician. Cleve Clin J Med. 2011;78(Suppl 2):S38\u201341.","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"9","key":"388_CR38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/2326-6066.CIR-15-0156","volume":"4","author":"S. Theurich","year":"2016","unstructured":"Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, et al. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res. 2016;4:744\u201354.","journal-title":"Cancer Immunology Research"},{"issue":"4","key":"388_CR39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"Stephen M. Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"388_CR40","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"Robert L. Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"New England Journal of Medicine"},{"key":"388_CR41","doi-asserted-by":"crossref","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","DOI":"10.1056\/NEJMoa1003466"},{"key":"388_CR42","doi-asserted-by":"crossref","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","DOI":"10.1016\/S1470-2045(15)00083-2"},{"issue":"17","key":"388_CR43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"Hossein Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"388_CR44","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"Leena Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"388_CR45","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"Robert J. Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33:1430\u20137.","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"388_CR46","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"Robert J. Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"388_CR47","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood-2017-10-752154","volume":"131","author":"Robert J. Soiffer","year":"2018","unstructured":"Soiffer RJ, Davids MS, Chen YB. Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018;131:1073\u201380.","journal-title":"Blood"},{"key":"388_CR48","doi-asserted-by":"crossref","unstructured":"Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1:2643\u201354.","DOI":"10.1182\/bloodadvances.2017012534"},{"key":"388_CR49","doi-asserted-by":"crossref","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270\u20131.","DOI":"10.1056\/NEJMoa1504030"},{"issue":"26","key":"388_CR50","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"Caroline Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"388_CR51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"Mary E. Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annual Review of Immunology"},{"key":"388_CR52","unstructured":"Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17\u201337."},{"issue":"8","key":"388_CR53","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M. Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537\u201344.","journal-title":"Blood"},{"issue":"9","key":"388_CR54","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood-2006-12-064360","volume":"110","author":"J. M. Chemnitz","year":"2007","unstructured":"Chemnitz JM, Eggle D, Driesen J, Classen S, Riley JL, Debey-Pascher S, et al. RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+T cells in Hodgkin lymphoma. Blood. 2007;110:3226\u201333.","journal-title":"Blood"},{"key":"388_CR55","doi-asserted-by":"crossref","unstructured":"Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297\u2013339.","DOI":"10.1016\/S0065-2776(06)90008-X"},{"issue":"19","key":"388_CR56","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"J. M. Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064\u201374.","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"388_CR57","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","volume":"13","author":"R. H. Thompson","year":"2007","unstructured":"Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757\u201361.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"388_CR58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/cmi.2010.28","volume":"7","author":"Yan Zhang","year":"2010","unstructured":"Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389\u201395.","journal-title":"Cellular & Molecular Immunology"},{"key":"388_CR59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"J.M. Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"European Journal of Cancer"},{"issue":"26","key":"388_CR60","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"Julie R. Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"388_CR61","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"Suzanne L. Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"388_CR62","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","volume":"32","author":"Mojtaba Akhtari","year":"2009","unstructured":"Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother. 2009;32:322\u20134.","journal-title":"Journal of Immunotherapy"},{"key":"388_CR63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2016.06.026","volume":"99","author":"Samer Tabchi","year":"2016","unstructured":"Tabchi S, Weng X, Blais N. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer. 2016;99:123\u20136.","journal-title":"Lung Cancer"},{"key":"388_CR64","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"G. Redelman-Sidi","year":"2018","unstructured":"Redelman-Sidi G, Michielin O, Cervera C, Ribi C, Aguado JM, Fern\u00e1ndez-Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors. Clin Microbiol Infect. 2018;24(Suppl 2):S95\u2013107.","journal-title":"Clinical Microbiology and Infection"},{"issue":"21","key":"388_CR65","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"Jeffrey S. Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691\u20137.","journal-title":"Journal of Clinical Oncology"},{"key":"388_CR66","doi-asserted-by":"crossref","unstructured":"Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63:1490\u20133.","DOI":"10.1093\/cid\/ciw539"},{"issue":"12","key":"388_CR67","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","volume":"11","author":"Kohei Fujita","year":"2016","unstructured":"Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. 2016;11:2238\u201340.","journal-title":"Journal of Thoracic Oncology"},{"issue":"7","key":"388_CR68","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1073\/pnas.0711918105","volume":"105","author":"E. Lazar-Molnar","year":"2008","unstructured":"L\u00e1z\u00e1r-Moln\u00e1r E, G\u00e1cser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD. The PD-1\/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci USA. 2008;105:2658\u201363.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"388_CR69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2567.2007.02708.x","volume":"123","author":"Su-Kil Seo","year":"2008","unstructured":"Seo SK, Jeong HY, Park SG, Lee SW, Choi IW, Chen, et al. Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection. Immunology. 2008;123:90\u20139.","journal-title":"Immunology"},{"issue":"11","key":"388_CR70","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.4049\/jimmunol.180.11.7553","volume":"180","author":"Jared H. Rowe","year":"2008","unstructured":"Rowe JH, Johanns TM, Ertelt JM, Way SS. PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes. J Immunol. 2008;180:7553\u20137.","journal-title":"The Journal of Immunology"},{"key":"388_CR71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"Lavinia Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treatment Reviews"},{"issue":"11","key":"388_CR72","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","volume":"10","author":"Lindsey Robert Baden","year":"2012","unstructured":"Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012;10:1412\u201345.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"6","key":"388_CR73","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","volume":"29","author":"C T Rieger","year":"2018","unstructured":"Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors\u2014Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2018;29:1354\u201365.","journal-title":"Annals of Oncology"},{"key":"388_CR74","doi-asserted-by":"crossref","unstructured":"Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.","DOI":"10.1038\/ncomms10391"},{"issue":"6","key":"388_CR75","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N. Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368\u201379.","journal-title":"Annals of Oncology"},{"issue":"25","key":"388_CR76","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"Jan A. Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"New England Journal of Medicine"},{"key":"388_CR77","doi-asserted-by":"crossref","unstructured":"Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously t reated chronic lymphoid leukemia. N Engl J Med. 2014;371:213\u201323.","DOI":"10.1056\/NEJMoa1400376"},{"key":"388_CR78","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","DOI":"10.1056\/NEJMoa1306220"},{"issue":"16","key":"388_CR79","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","volume":"129","author":"Ariela Noy","year":"2017","unstructured":"Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood. 2017;129:2224\u201332.","journal-title":"Blood"},{"issue":"2","key":"388_CR80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"Asher Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200\u201311.","journal-title":"The Lancet Oncology"},{"key":"388_CR81","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al.; iNNOVATE Study Group and the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia. Ibrutinib for patients with rituximab-refr actory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241\u201350.","DOI":"10.1016\/S1470-2045(16)30632-5"},{"issue":"21","key":"388_CR82","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"David Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243\u201350.","journal-title":"Blood"},{"key":"388_CR83","doi-asserted-by":"crossref","unstructured":"Satterthwaite AB, Witte ON. The role of Bruton\u2019s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120\u20137.","DOI":"10.1111\/j.1600-065X.2000.imr017504.x"},{"key":"388_CR84","doi-asserted-by":"crossref","unstructured":"Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722\u20138.","DOI":"10.1542\/peds.9.6.722"},{"key":"388_CR85","doi-asserted-by":"crossref","unstructured":"Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton\u2019s Tyrosine Kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454.","DOI":"10.3389\/fimmu.2017.01454"},{"issue":"16","key":"388_CR86","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"J. C. Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497\u2013506.","journal-title":"Blood"},{"key":"388_CR87","doi-asserted-by":"crossref","unstructured":"Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126:2213\u20139.","DOI":"10.1182\/blood-2015-04-639203"},{"key":"388_CR88","doi-asserted-by":"crossref","unstructured":"Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Open Forum Infect Dis. 2017;4:ofw261.","DOI":"10.1093\/ofid\/ofw261"},{"key":"388_CR89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4642831","volume":"2016","author":"Koh Okamoto","year":"2016","unstructured":"Okamoto K, Proia LA, Demarais PL. Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis. 2016;2016:4642831.","journal-title":"Case Reports in Infectious Diseases"},{"issue":"3","key":"388_CR90","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/1078155217752078","volume":"25","author":"Matthew Stankowicz","year":"2018","unstructured":"Stankowicz M, Banaszynski M, Crawford R. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia. J Oncol Pharm Pract. 2018:1078155217752078. https:\/\/doi.org\/10.1177\/1078155217752078 [Epub ahead of print].","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"388_CR91","doi-asserted-by":"crossref","unstructured":"Sun K, Kasparian S, Iyer S, Pingali SR. Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Ecancermedicalscience. 2018;12:836.","DOI":"10.3332\/ecancer.2018.836"},{"issue":"3","key":"388_CR92","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jdcr.2017.01.027","volume":"3","author":"Josh A. Hammel","year":"2017","unstructured":"Hammel JA, Roth GM, Ferguson N, Fairley JA. Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia. JAAD Case Rep. 2017;3:178\u20139.","journal-title":"JAAD Case Reports"},{"issue":"8","key":"388_CR93","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00277-015-2385-0","volume":"94","author":"Song-Yau Wang","year":"2015","unstructured":"Wang SY, Ebert T, Jaekel N, Schubert S, Niederwieser D, Al-Ali HK. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. Ann Hematol. 2015;94:1419\u201320.","journal-title":"Annals of Hematology"},{"issue":"2","key":"388_CR94","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bjh.14322","volume":"180","author":"Charles L. Bennett","year":"2016","unstructured":"Bennett CL, Berger JR, Sartor O, Carson KR, Hrushesky WJ, Georgantopoulos P, et al. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018;180:301\u20134.","journal-title":"British Journal of Haematology"},{"issue":"5","key":"388_CR95","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000490617","volume":"95","author":"David Hsiehchen","year":"2018","unstructured":"Hsiehchen D, Arasaratnam R, Raj K, Froehlich T, Anderson L. Ibrutinib use complicated by progressive multifocal leukoencephalopathy. Oncology. 2018;95:319\u201322.","journal-title":"Oncology"},{"issue":"2","key":"388_CR96","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4143\/crt.2016.110","volume":"49","author":"Mathias Lutz","year":"2017","unstructured":"Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, et al. Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Res Treat. 2017;49:548\u201352.","journal-title":"Cancer Research and Treatment"},{"key":"388_CR97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lrr.2017.01.002","volume":"7","author":"Maurizio Cavallari","year":"2017","unstructured":"Cavallari M, Ciccone M, Falzoni S, Cavazzini F, Formigaro L, Di Virgilio F, et al. Hemophagocytic lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed\/refractory chronic lymphocytic leukemia. Leuk Res Rep. 2017;7:11\u20133.","journal-title":"Leukemia Research Reports"},{"issue":"17","key":"388_CR98","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","volume":"131","author":"Sarah P. Hammond","year":"2018","unstructured":"Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018;131:1987\u20139.","journal-title":"Blood"},{"issue":"4","key":"388_CR99","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00277-016-2917-2","volume":"96","author":"Yair Herishanu","year":"2017","unstructured":"Herishanu Y, Katchman H, Polliack A. Severe hepatitis B virus reactivation related to ibrutinib monotherapy. Ann Hematol. 2017;96:689\u201390.","journal-title":"Annals of Hematology"},{"issue":"15","key":"388_CR100","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","volume":"128","author":"Inhye E. Ahn","year":"2016","unstructured":"Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940\u20133.","journal-title":"Blood"},{"issue":"11","key":"388_CR101","doi-asserted-by":"crossref","first-page":"E646","DOI":"10.1002\/ajh.24890","volume":"92","author":"Regina Lee","year":"2017","unstructured":"Lee R, Nayernama A, Jones SC, Wroblewski T, Waldron PE. Ibrutinib-associated Pneumocystis jirovecii pneumonia. Am J Hematol. 2017;92:E646\u20138.","journal-title":"American Journal of Hematology"},{"issue":"17","key":"388_CR102","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"David Ghez","year":"2018","unstructured":"Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al.; French Innovative Leukemia Organization (FILO) CLL group. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955\u20139.","journal-title":"Blood"},{"key":"388_CR103","doi-asserted-by":"crossref","unstructured":"Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid malignancies. Clin Infect Dis. 2018;67:687\u201392.","DOI":"10.1093\/cid\/ciy175"},{"issue":"6","key":"388_CR104","first-page":"833-843.e5","volume":"31","author":"Michail S. Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833\u201343.","journal-title":"Cancer Cell"},{"issue":"6","key":"388_CR105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ccell.2017.05.004","volume":"31","author":"Christian Grommes","year":"2017","unstructured":"Grommes C, Younes A. Ibrutinib in PCNSL: the curios cases of clinical responses and aspergillosis. Cancer Cell. 2017;31:731\u20133.","journal-title":"Cancer Cell"},{"issue":"1","key":"388_CR106","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","volume":"66","author":"Georgios Chamilos","year":"2017","unstructured":"Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018;66:140\u20138.","journal-title":"Clinical Infectious Diseases"},{"key":"388_CR107","doi-asserted-by":"crossref","unstructured":"de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 2016;100:548\u201357.","DOI":"10.1002\/cpt.419"},{"issue":"3","key":"388_CR108","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/17474086.2016.1129893","volume":"9","author":"Jasleen K. Randhawa","year":"2016","unstructured":"Randhawa JK, Ferrajoli A. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2016;9:235\u201344.","journal-title":"Expert Review of Hematology"},{"issue":"5","key":"388_CR109","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bjh.14855","volume":"182","author":"Benjamin Andrick","year":"2017","unstructured":"Andrick B, Alwhaibi A, DeRemer DL, Quershi S, Khan R, Bryan LJ, et al. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2018;182:712\u20134.","journal-title":"British Journal of Haematology"},{"issue":"10","key":"388_CR110","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","volume":"102","author":"Abby P. Douglas","year":"2017","unstructured":"Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102:e397\u20139.","journal-title":"Haematologica"},{"key":"388_CR111","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2015-12-686873","volume":"127","author":"AR Mato","year":"2016","unstructured":"Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2016;127:1064\u20137.","journal-title":"Blood"},{"key":"388_CR112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","volume":"13","author":"B Vanhaesebroeck","year":"2012","unstructured":"Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13:195\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"388_CR113","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"Bart Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:32941.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"9","key":"388_CR114","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.4049\/jimmunol.0900432","volume":"183","author":"Caylib A. Durand","year":"2009","unstructured":"Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B, et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol. 2009;183:5673\u201384.","journal-title":"The Journal of Immunology"},{"key":"388_CR115","doi-asserted-by":"crossref","unstructured":"Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood. 2006;107:642\u201350.","DOI":"10.1182\/blood-2005-07-3041"},{"issue":"2","key":"388_CR116","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"B. J. Lannutti","year":"2010","unstructured":"Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591\u20134.","journal-title":"Blood"},{"issue":"13","key":"388_CR117","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J. Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603\u201312.","journal-title":"Blood"},{"issue":"16","key":"388_CR118","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","volume":"117","author":"S. E. M. Herman","year":"2011","unstructured":"Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, et al. The role of phosphatidylinositol 3-kinase-\u03b4 in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117:4323\u20137.","journal-title":"Blood"},{"key":"388_CR119","doi-asserted-by":"crossref","unstructured":"Alflen A, Stadler N, Aranda Lopez P, Teschner D, Theobald M, He\u00df G, et al. Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses. Sci Rep. 2018;8:5558.","DOI":"10.1038\/s41598-018-23808-2"},{"issue":"22","key":"388_CR120","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"I. W. Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406\u201313.","journal-title":"Blood"},{"issue":"11","key":"388_CR121","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"Ajay K. Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008\u201318.","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"388_CR122","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"B. S. Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398\u2013405.","journal-title":"Blood"},{"issue":"22","key":"388_CR123","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"J. R. Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390\u20137.","journal-title":"Blood"},{"issue":"11","key":"388_CR124","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"Richard R. Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"388_CR125","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","volume":"126","author":"S. M. O'Brien","year":"2015","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686\u201394.","journal-title":"Blood"},{"issue":"3","key":"388_CR126","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","volume":"4","author":"Jeffrey A Jones","year":"2017","unstructured":"Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4:e114\u201326.","journal-title":"The Lancet Haematology"},{"issue":"3","key":"388_CR127","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","volume":"18","author":"Andrew D Zelenetz","year":"2017","unstructured":"Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18:297\u2013311.","journal-title":"The Lancet Oncology"},{"issue":"20","key":"388_CR128","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"P. M. Barr","year":"2016","unstructured":"Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O\u2019Brien SM, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127:2411\u20135.","journal-title":"Blood"},{"issue":"4","key":"388_CR129","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","volume":"4","author":"Sonali M Smith","year":"2017","unstructured":"Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, et al. Safety and tolerability of idelalisib, lenalidomide and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4:e176\u201382.","journal-title":"The Lancet Haematology"},{"issue":"21","key":"388_CR130","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","volume":"125","author":"C. Y. Cheah","year":"2015","unstructured":"Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma. Blood. 2015;125:3357\u20139.","journal-title":"Blood"},{"key":"388_CR131","doi-asserted-by":"crossref","unstructured":"Sehn LH, Hallek M, Jurczak W, Brown JR, Barr PM, Catalano J, et al. A retrospective analysis of Pneumocystis jirovecii pneumonia infection in patients receiving idelalisib in clinical trials. Blood. 2016;128:3705.","DOI":"10.1182\/blood.V128.22.3705.3705"},{"key":"388_CR132","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","volume":"24","author":"M. Reinwald","year":"2018","unstructured":"Reinwald M, Silva JT, Mueller NJ, Fort\u00fan J, Garzoni C, de Fijter JW, et al. ESCMID Study group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24:S53\u201370. Suppl 2","journal-title":"Clinical Microbiology and Infection"},{"key":"388_CR133","unstructured":"Zydelig Prescribing Information. http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/oncology\/zydelig\/zydelig_pi.pdf . Accessed 5 August 2018."},{"issue":"3","key":"388_CR134","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","volume":"128","author":"C. Y. Cheah","year":"2016","unstructured":"Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128:331\u20136.","journal-title":"Blood"},{"key":"388_CR135","unstructured":"https:\/\/www.ema.europa.eu\/documents\/variation-report\/zydelig-h-c-003843-a20-1439-0023-epar-assessment-report-article-20_en.pdf"},{"issue":"32","key":"388_CR136","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"Andrew A. Lane","year":"2009","unstructured":"Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459\u201368.","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"388_CR137","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-05-284711","volume":"117","author":"T. Roger","year":"2010","unstructured":"Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood. 2011;117:1205\u201317.","journal-title":"Blood"},{"issue":"4","key":"388_CR138","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2010-11-315820","volume":"117","author":"K. A. Bode","year":"2011","unstructured":"Bode KA, Dalpke AH. HDAC inhibitors block innate immunity. Blood. 2011;117:1202\u20133.","journal-title":"Blood"},{"issue":"6","key":"388_CR139","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"Bertrand Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"Journal of Clinical Oncology"},{"issue":"29","key":"388_CR140","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"Sean J. Whittaker","year":"2010","unstructured":"Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485\u201391.","journal-title":"Journal of Clinical Oncology"},{"key":"388_CR141","doi-asserted-by":"crossref","unstructured":"Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, et al. Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma. Biomark Res. 2014;2:16.","DOI":"10.1186\/2050-7771-2-16"},{"issue":"9","key":"388_CR142","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2015-0043","volume":"20","author":"S. P. Iyer","year":"2015","unstructured":"Iyer SP, Foss FF. Romidepsin for the treatment of peripheral T-cell lymphoma. Oncologist. 2015;20:1084\u201391.","journal-title":"The Oncologist"},{"issue":"3","key":"388_CR143","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/1078-0432.CCR-07-0318","volume":"14","author":"V. M. Klimek","year":"2008","unstructured":"Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008;14:826\u201332.","journal-title":"Clinical Cancer Research"},{"key":"388_CR144","doi-asserted-by":"crossref","unstructured":"Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127:713\u201321.","DOI":"10.1182\/blood-2015-09-665018"},{"key":"388_CR145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.07.001","volume":"106","author":"Sunil A. Reddy","year":"2016","unstructured":"Reddy SA. Romidepsin for the treatment of relapsed\/refractory cutaneous T-cell lymphoma (mycosis fungoides\/S\u00e9zary syndrome): use in a community setting. Crit Rev Oncol Hematol. 2016;106:99\u2013107.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"18","key":"388_CR146","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","volume":"30","author":"Anas Younes","year":"2012","unstructured":"Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197\u2013203.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"388_CR147","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.12230","volume":"161","author":"Lihua E. Budde","year":"2013","unstructured":"Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, et al. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol. 2013;161:183\u201391.","journal-title":"British Journal of Haematology"},{"issue":"9","key":"388_CR148","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ajh.23778","volume":"89","author":"Michael J. Burke","year":"2014","unstructured":"Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Haematol. 2014;89:889\u201395.","journal-title":"American Journal of Hematology"},{"issue":"32","key":"388_CR149","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"Richard L. Piekarz","year":"2009","unstructured":"Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27:5410\u201317.","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"388_CR150","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"R. L. Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827\u201334.","journal-title":"Blood"},{"issue":"8","key":"388_CR151","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/blood-2012-06-439307","volume":"121","author":"I. M. Ghobrial","year":"2013","unstructured":"Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia. Blood. 2013;121:1296\u2013303.","journal-title":"Blood"},{"issue":"7408","key":"388_CR152","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"N. M. Archin","year":"2012","unstructured":"Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482\u20135.","journal-title":"Nature"},{"key":"388_CR153","doi-asserted-by":"crossref","unstructured":"Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, et al. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Retrovirology. 2016;13:36.","DOI":"10.1186\/s12977-016-0268-7"},{"issue":"20","key":"388_CR154","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1128\/JVI.01484-15","volume":"89","author":"Rikke Olesen","year":"2015","unstructured":"Olesen R, Vigano S, Rasmussen TA, S\u00f8gaard OS, Ouyang Z, Buzon M, et al. Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J Virol. 2015;89:10176\u201389.","journal-title":"Journal of Virology"},{"issue":"8","key":"388_CR155","doi-asserted-by":"crossref","first-page":"e1004287","DOI":"10.1371\/journal.ppat.1004287","volume":"10","author":"Richard Brad Jones","year":"2014","unstructured":"Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog. 2014;10:e1004287.","journal-title":"PLoS Pathogens"},{"issue":"8","key":"388_CR156","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"Sandrine Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671\u201388.","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"388_CR157","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/1078-0432.CCR-14-3239","volume":"22","author":"A. M. Eiden","year":"2015","unstructured":"Eiden AM, Zhang S, Gary JM, Simmons JK, Mock BA. Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy. Clin Cancer Res. 2016;22:277\u201383.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"388_CR158","first-page":"67","volume":"30","author":"Jian Xu","year":"2013","unstructured":"Xu J, Tian D. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin. 2014;30:67\u201374.","journal-title":"Current Medical Research and Opinion"},{"issue":"12","key":"388_CR159","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/bjc.2013.278","volume":"108","author":"M D Kaymakcalan","year":"2013","unstructured":"Kaymakcalan MD, Je Y, Sonpavde G, Galsky M, Nguyen PL, Heng DY, et al. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. 2013;108:2478\u201384.","journal-title":"British Journal of Cancer"},{"key":"388_CR160","doi-asserted-by":"crossref","unstructured":"De Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. Clin Microbiol Infect. 2010;16:1375\u20137.","DOI":"10.1111\/j.1469-0691.2010.03143.x"},{"key":"388_CR161","doi-asserted-by":"crossref","unstructured":"Xie X, Jiang Y, Lai X, Xiang S, Shou Z, Chen J. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. BMC Nephrol. 2015;16:91.","DOI":"10.1186\/s12882-015-0078-5"},{"key":"388_CR162","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","volume":"265","author":"Douglas L. Jennings","year":"2018","unstructured":"Jennings DL, Lange N, Shullo M, Latif F, Restaino S, Topkara VK, et al. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis. Int J Cardiol. 2018;265:71\u20136.","journal-title":"International Journal of Cardiology"},{"issue":"8","key":"388_CR163","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mds115","volume":"23","author":"L. Albiges","year":"2012","unstructured":"Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol. 2012;23:1943\u201353.","journal-title":"Annals of Oncology"},{"issue":"7","key":"388_CR164","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3109\/0284186X.2012.705019","volume":"51","author":"Roberto Iacovelli","year":"2012","unstructured":"Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol. 2012;51:873\u20139.","journal-title":"Acta Oncologica"},{"issue":"6","key":"388_CR165","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3109\/0284186X.2013.770166","volume":"52","author":"Anna E. C. A. B. Willemsen","year":"2013","unstructured":"Willemsen AE, van Herpen CM. mTOR inhibitor-related pulmonary toxicity; incidence even higher. Acta Oncol. 2013;52:1234.","journal-title":"Acta Oncologica"},{"issue":"7","key":"388_CR166","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2013-07-509612","volume":"122","author":"A. Tefferi","year":"2013","unstructured":"Tefferi A. Ruxolitinib targets DCs: for better or worse? Blood. 2013;122:1096\u20137.","journal-title":"Blood"},{"issue":"7","key":"388_CR167","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A. Heine","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192\u2013202.","journal-title":"Blood"},{"issue":"6","key":"388_CR168","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","volume":"169","author":"Sowmya Parampalli Yajnanarayana","year":"2015","unstructured":"Parampalli Yajnanarayana S, St\u00fcbig T, Cornez I, Alchalby H, Sch\u00f6nberg K, Rudolph J, et al. JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169:824\u201333.","journal-title":"British Journal of Haematology"},{"issue":"1","key":"388_CR169","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.13519","volume":"171","author":"Clodagh Keohane","year":"2015","unstructured":"Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171:60\u201373.","journal-title":"British Journal of Haematology"},{"issue":"2","key":"388_CR170","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","volume":"28","author":"M Massa","year":"2013","unstructured":"Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014;28:449\u201351.","journal-title":"Leukemia"},{"issue":"1","key":"388_CR171","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","volume":"194","author":"Alejandro V. Villarino","year":"2014","unstructured":"Villarino AV, Kanno Y, Ferdinand JR, O\u2019Shea JJ. Mechanisms of JAK\/STAT signaling in immunity and disease. J Immunol. 2015;194:21\u20137.","journal-title":"The Journal of Immunology"},{"issue":"11","key":"388_CR172","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","volume":"75","author":"Kathrin Sch\u00f6nberg","year":"2015","unstructured":"Sch\u00f6nberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, et al. JAK Inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187\u201399.","journal-title":"Cancer Research"},{"issue":"13","key":"388_CR173","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F. Cervantes","year":"2008","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"issue":"9","key":"388_CR174","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F. Passamonti","year":"2009","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703\u20138.","journal-title":"Blood"},{"issue":"4","key":"388_CR175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S. Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479\u201388.","journal-title":"Haematologica"},{"key":"388_CR176","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55.","DOI":"10.1186\/s13045-017-0417-z"},{"issue":"9","key":"388_CR177","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"Claire Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK Inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"New England Journal of Medicine"},{"key":"388_CR178","doi-asserted-by":"crossref","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701\u20137.","DOI":"10.1038\/leu.2016.148"},{"issue":"1","key":"388_CR179","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"Adam J. Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, et al. Response to ruxolitinib in patients with intermediate-1\u2013, intermediate-2\u2013, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015;170:29\u201339.","journal-title":"British Journal of Haematology"},{"issue":"9","key":"388_CR180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"H. K. Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, et al. Safety and efficacy of ruxolitinib in an open label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101:1065\u201373.","journal-title":"Haematologica"},{"issue":"5","key":"388_CR181","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"Alessandro M. Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"388_CR182","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"Francesco Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18:88\u201399.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"388_CR183","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","volume":"92","author":"Nicola Polverelli","year":"2016","unstructured":"Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92:37\u201341.","journal-title":"American Journal of Hematology"},{"issue":"1","key":"388_CR184","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.13758","volume":"174","author":"Francesca Palandri","year":"2015","unstructured":"Palandri F, Polverelli N, Breccia M, Nicolino B, Vitolo U, Alimena G, et al. Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. Br J Haematol. 2016;174:160\u20132.","journal-title":"British Journal of Haematology"},{"issue":"2","key":"388_CR185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","volume":"369","author":"Rowan Wathes","year":"2013","unstructured":"Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369:197\u20138.","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"388_CR186","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","volume":"369","author":"Roger A. Goldberg","year":"2013","unstructured":"Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369:681\u20133.","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"388_CR187","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1413918","volume":"374","author":"Joanna von Hofsten","year":"2016","unstructured":"Von Hofsten J, Johnsson Forsberg M, Zetteberg M. Cytomegalovirus retinitis in a patient who received ruxolitinib. N Engl J Med. 2016;374:296\u20137.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"388_CR188","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","volume":"143","author":"Nicholas G. Wysham","year":"2013","unstructured":"Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143:1478\u20139.","journal-title":"Chest"},{"key":"388_CR189","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.rmcr.2017.06.015","volume":"22","author":"Anna Hirano","year":"2017","unstructured":"Hirano A, Yamasaki M, Saito N, Iwato K, Daido W, Funaishi K, et al. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis. Respir Med Case Rep. 2017;22:87\u201390.","journal-title":"Respiratory Medicine Case Reports"},{"issue":"2","key":"388_CR190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-015-2532-7","volume":"95","author":"Chih-Cheng Chen","year":"2015","unstructured":"Chen CC, Chen YY, Huang CE. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol. 2016;95:361\u20132.","journal-title":"Annals of Hematology"},{"issue":"7","key":"388_CR191","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3201\/eid2107.150138","volume":"21","author":"Jasper F.W. Chan","year":"2015","unstructured":"Chan JF, Chan TS, Gill H, Lam FY, Trendell-Smith NJ, Sridhar S, et al. Disseminated infections with Talaromyces marneffei in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. Emerg Infect Dis. 2015;21:1101\u20136.","journal-title":"Emerging Infectious Diseases"},{"issue":"jun02 1","key":"388_CR192","doi-asserted-by":"publisher","first-page":"bcr2014204950","DOI":"10.1136\/bcr-2014-204950","volume":"2014","author":"S. C. Lee","year":"2014","unstructured":"Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. 2014; pii bcr2014204950. Published online 2014 Jun 2. https:\/\/doi.org\/10.1136\/bcr-2014-204950 .","journal-title":"Case Reports"},{"key":"388_CR193","unstructured":"Kn\u00f6dler A, Schmiedel S, Sch\u00e4fer G, Bokemeyer C, von Amsberg G. Pneumocystis jirovecii pneumonia associated with ruxolitinib therapy in a patient with myelofibrosis. Oncol Res Treat. 2014;37:164\u20135."},{"key":"388_CR194","doi-asserted-by":"crossref","unstructured":"P\u00e1lmason R, Lind\u00e9n O, Richter J. Case-report: EBV driven lymphoproliferative disorder associated with ruxolitinib. BMC Hematol. 2015;15:10.","DOI":"10.1186\/s12878-015-0029-1"},{"issue":"10","key":"388_CR195","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00277-016-2748-1","volume":"95","author":"Yoshiharu Kusano","year":"2016","unstructured":"Kusano Y, Terui Y, Ueda K, Hatake K. Epstein-Barr virus gastric ulcer associated with ruxolitinib. Ann Hematol. 2016;95:1741\u20132.","journal-title":"Annals of Hematology"},{"issue":"5","key":"388_CR196","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ajh.24688","volume":"92","author":"Ophir Eyal","year":"2017","unstructured":"Eyal O, Flaschner M, Ben Yehuda A, Rund D. Varicella-zoster virus meningoencephalitis in a patient treated with ruxolitinib. Am J Hematol. 2017;92:E74\u20135.","journal-title":"American Journal of Hematology"},{"issue":"1","key":"388_CR197","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","volume":"28","author":"G Caocci","year":"2013","unstructured":"Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28:225\u20137.","journal-title":"Leukemia"},{"issue":"6","key":"388_CR198","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","volume":"93","author":"Chien-Heng Shen","year":"2013","unstructured":"Shen CH, Hwang CE, Chen YY, Chen CC. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol. 2014;93:1075\u20136.","journal-title":"Annals of Hematology"},{"issue":"10","key":"388_CR199","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2169\/internalmedicine.55.5529","volume":"55","author":"Keita Kirito","year":"2016","unstructured":"Kirito K, Sakamoto M, Enomoto N. Elevation of the hepatitis B virus DNA during the treatment of Polycythemia Vera with the JAK kinase inhibitor ruxolitinib. Intern Med. 2016;55:1341\u20134.","journal-title":"Internal Medicine"},{"issue":"6","key":"388_CR200","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.dld.2017.03.004","volume":"49","author":"Giovanni Perricone","year":"2017","unstructured":"Perricone G, Vinci M, Pungolino E. Occult hepatitis B infection reactivation after ruxolitinib therapy. Dig Liver Dis. 2017;49:719.","journal-title":"Digestive and Liver Disease"},{"key":"388_CR201","doi-asserted-by":"crossref","unstructured":"Mallet V, van B\u00f6mmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, et al. Management of viral hepatitis in patients undergoing haematopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukemia (ECIL-5). Lancet Infect Dis. 2016;16:606\u201317.","DOI":"10.1016\/S1473-3099(16)00118-3"},{"issue":"1","key":"388_CR202","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"K. Rajender Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215\u20139.","journal-title":"Gastroenterology"},{"key":"388_CR203","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. European Association for the Study of the Liver clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","DOI":"10.1016\/j.jhep.2012.02.010"},{"issue":"23","key":"388_CR204","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","volume":"122","author":"A. Heine","year":"2013","unstructured":"Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122:3843\u20134.","journal-title":"Blood"},{"key":"388_CR205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/284168","volume":"2015","author":"Eamon Shamil","year":"2015","unstructured":"Shamil E, Cunningham D, Wong BL, Jani P. Ruxolitinib associated tuberculosis presenting as a neck lump. Case Rep Infect Dis. 2015;2015:284168.","journal-title":"Case Reports in Infectious Diseases"},{"key":"388_CR206","doi-asserted-by":"crossref","unstructured":"Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012;5:552.","DOI":"10.1186\/1756-0500-5-552"},{"issue":"8","key":"388_CR207","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/leu.2014.104","volume":"28","author":"R K Hopman","year":"2014","unstructured":"Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia. 2014;28:1750\u20131.","journal-title":"Leukemia"},{"issue":"3","key":"388_CR208","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-014-2183-0","volume":"94","author":"Francesca Palandri","year":"2014","unstructured":"Palandri F, Polverelli N, Catani L, Vianelli N. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015;94:519\u201320.","journal-title":"Annals of Hematology"},{"key":"388_CR209","unstructured":"Keizer S, Gerritsen R, Jauw Y, Janssen J, Koopman B, Bresser P. Fatal tuberculosis during treatment with ruxolitinib. Ned Tijdschr Geneeskd. 2015;159:A8650."},{"issue":"5","key":"388_CR210","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3109\/10428194.2014.963082","volume":"56","author":"Yen-Hao Chen","year":"2014","unstructured":"Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015;56:1528\u20139.","journal-title":"Leukemia & Lymphoma"},{"issue":"7","key":"388_CR211","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-016-2684-0","volume":"95","author":"Benoit Branco","year":"2016","unstructured":"Branco B, Metsu D, Dutertre M, Marchou B, Delobel P, Recher C, et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol. 2016;95:1207\u20139.","journal-title":"Annals of Hematology"},{"key":"388_CR212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2389038","volume":"2016","author":"Maheen Z. Abidi","year":"2016","unstructured":"Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, et al. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol. 2016;2016:2389038.","journal-title":"Case Reports in Hematology"},{"key":"388_CR213","unstructured":"Malkan UY, Haznedaroglu IC. A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment. Int J Clin Exp Med. 2017;10:7304\u20137."},{"issue":"3","key":"388_CR214","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hon.2509.","volume":"36","author":"Nicola Polverelli","year":"2018","unstructured":"Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, et al. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematol Oncol. 2018. https:\/\/doi.org\/10.1002\/hon.2509.","journal-title":"Hematological Oncology"},{"issue":"3","key":"388_CR215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"Federico Lussana","year":"2017","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93:339\u201347.","journal-title":"American Journal of Hematology"},{"key":"388_CR216","doi-asserted-by":"crossref","unstructured":"Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86:1188\u201391.","DOI":"10.4065\/mcp.2011.0518"},{"issue":"12","key":"388_CR217","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/bmt.2016.256","volume":"51","author":"Y Mori","year":"2016","unstructured":"Mori Y, Ikeda K, Inomata T, Yoshimoto G, Fujii N, Ago H, et al. Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant. 2016;51:1584\u20137.","journal-title":"Bone Marrow Transplantation"},{"key":"388_CR218","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/DDDT.S109325","volume":"Volume11","author":"Huayuan Zhu","year":"2017","unstructured":"Zhu H, Almasan A. Development of venetoclax for therapy of lymphoid malignancies. Drug Des Devel Ther. 2017;11:685\u201394.","journal-title":"Drug Design, Development and Therapy"},{"issue":"4","key":"388_CR219","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"Andrew W. Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"388_CR220","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"Stephan Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768\u201378.","journal-title":"The Lancet Oncology"},{"issue":"5","key":"388_CR221","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40262-016-0453-9","volume":"56","author":"Kevin J. Freise","year":"2016","unstructured":"Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, et al. Impact of venetoclax esposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet. 2017;56:515\u201323.","journal-title":"Clinical Pharmacokinetics"},{"issue":"279","key":"388_CR222","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"Joel D. Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40.","journal-title":"Science Translational Medicine"},{"issue":"12","key":"388_CR223","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"John F. Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"388_CR224","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/0961203317719334","volume":"27","author":"P Lu","year":"2017","unstructured":"Lu P, Fleischmann R, Curtis C, Ignatenko S, Clarke SH, Desai M, et al. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus. 2018;27:290\u2013302.","journal-title":"Lupus"},{"issue":"18","key":"388_CR225","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","volume":"24","author":"Matthew S. Davids","year":"2018","unstructured":"Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24:4371\u20139.","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"388_CR226","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"John F Seymour","year":"2017","unstructured":"Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230\u201340.","journal-title":"The Lancet Oncology"},{"key":"388_CR227","unstructured":"Venclexta Prescribing Information. https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf . Accessed 5 August 2018."},{"issue":"2","key":"388_CR228","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"Suresh K. Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax - posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39:359\u201367.","journal-title":"Clinical Therapeutics"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0388-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:36:46Z","timestamp":1684618606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":228,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0388-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"19 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GM accepted honoraria for lectures from Gilead, Pfizer, Boehringer Ingelheim, Celgene, Bristol-Myers Squibb, Merck-Serono, Novartis, honorarium for advice from Gilead and a travel grant from Bristol-Myers Squibb. JAM accepted grants, personal fees and nonfinancial support from MSD, Astellas, Pfizer and Gilead, personal fees and nonfinancial support from Basilea and F2G and personal fees from Scynexis. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}